<DOC>
	<DOCNO>NCT02187744</DOCNO>
	<brief_summary>The current study compare PK , efficacy , safety , immunogenicity PF-05280014 ( Trastuzumab-Pfizer ) combination Taxotere® Carboplatin ( Paraplatin ) versus Herceptin® ( Trastuzumab-EU ) approve EU combination Taxotere® Carboplatin ( Paraplatin ) patient operable HER2 positive , breast cancer neoadjuvant setting . The hypothesis test study percentage patient steady state Cycle 5 Ctrough ( Cycle 6 pre-dose ) &gt; 20 µg/mL trastuzumab-Pfizer similar EU-approved trastuzumab , use margin -12.5 % .</brief_summary>
	<brief_title>A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting ( REFLECTIONS B327-04 )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Histologically confirm HER2 overexpressing invasive breast cancer . Plan definitive surgical resection breast tumor ( i.e. , lumpectomy mastectomy , sentinel node ( SN ) biopsy axillary lymph node dissection ( ALND ) . Plan neoadjuvant chemotherapy . Measurable disease breast diagnostic biopsy , define long diameter ≥ 2.0 cm . Bilateral breast cancer . Inflammatory breast cancer . Presence know distant metastasis . Received prior treatment , include chemotherapy , endocrine therapy , biologic therapy , radiation surgery exception diagnostic biopsy primary breast cancer .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Biosimilars</keyword>
	<keyword>Non-inferiority</keyword>
	<keyword>Neoadjuvant Setting</keyword>
	<keyword>Early Breast Cancer</keyword>
	<keyword>PK</keyword>
	<keyword>Phase 3</keyword>
	<keyword>Trastuzumab</keyword>
	<keyword>Herceptin</keyword>
	<keyword>HER2 Positive</keyword>
</DOC>